Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
Sanofi said its dupixent drug achieved significant improvements for the treatment of two skin diseases. The French pharmaceutical company said Wednesday that the drug met the primary and all key ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...
Drug meets primary and all secondary goals in COPD trial Previous peak sales estimate of 13 bln euros was without COPD Drug could be first new COPD treatment in over a decade March 23 (Reuters) - ...
The U.S. Food and Drug Administration (FDA) announced the approval of Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and children ages 12 and older on May 21, 2022. The drug is ...
Sanofi SAN posted first-quarter results largely in line with our projections, and we don’t expect any major changes to the firm’s fair value estimate. The stock looks undervalued with the market not ...
Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback